Drug Trial Radar · NCT04525729
Rituximab and RASi in Patients with IgAN
Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Jul 1, 2020
Primary completion
Mar 30, 2024
Study completion Mar 30, 2024
Sponsor
- Lead sponsor
- Nan Chen,MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Dongfang Hospital Affiliated to Tongji University; Shanghai Pudong New Area People's Hospital; Ruijin Hospital; Ningbo Municipal Yinzhou District No.2 Hospital; Third Affiliated Hospital, Sun Yat-Sen University; Xiamen Hong'ai Hospital; Sir Run Run Shaw Hospital; Tongji Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- First posted
- Aug 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.
Conditions
- IgA Nephropathy
Interventions
RituximabDrug
To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.
RAS 2410Drug
To evaluate the efficacy and safety of RASi in patients with IgAN.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in proteinuria levels over 1 year compared with baselineTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.